Scandinavian Journal of Medicine and Science in Sports,
Journal Year:
2025,
Volume and Issue:
35(3)
Published: March 1, 2025
Subjective
well-being
(SWB),
including
cognitive
and
affective
components,
may
be
influenced
by
the
management
of
type
1
diabetes
mellitus
(T1DM).
Physical
fitness
adherence
to
physical
activity
(PA)
are
associated
with
better
glycaemic
stability
management.
However,
relationship
SWB
is
not
yet
understood.
The
aim
study
was
determine
between
fitness,
PA,
over
two
years
in
youths
T1DM.
This
longitudinal
involved
83
participants
(aged
6-18
years;
44.6%
girls)
from
Diactive-1
Cohort.
assessed
spirometry
(peak
oxygen
consumption)
dynamometry
(handgrip
strength).
PA
domains
were
measured
using
triaxial
accelerometers,
whereas
number
days
participating
muscle-strengthening
activities
a
question.
Cuestionario
Único
de
Bienestar
Escolar
used
SWB.
Glycaemic
determined
when
glycosylated
hemoglobin
<
7%,
coefficient
variability
≤
36%,
time-in-range
target
>
70%
met.
linear
mixed
models
considered
three
assessments
subject
variability,
showing
significant
associations
overall
(unstandardized
beta
[B]
=
1.778,
95%
confidence
interval
[CI]
0.413-3.158;
p
0.012)
total
(B
0.034,
CI
0.005-0.063;
0.020)
Although
time
did
moderate
association
(p
0.116),
this
true
for
only
second
year
0.020).
In
contrast,
0.05).
conclusion,
greater
young
people
T1DM,
which
play
role
psychological
aspects
disease
Hepatology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: May 8, 2024
Metabolic
dysfunction–associated
steatotic
liver
disease
(MASLD),
previously
known
as
NAFLD,
is
increasingly
recognized
a
prevalent
global
burden.
Type
2
diabetes
mellitus
(T2DM),
another
important
metabolic
disease,
considered
major
contributor
to
the
development
of
MASLD.
MASLD
and
T2DM
have
strong
association
with
each
other
due
shared
pathogenic
mechanisms.
The
co-existence
diseases
increases
risk
liver-related
adverse
outcomes
imposes
heavier
burden
on
extrahepatic
outcomes,
representing
substantial
public
health
issue.
Effective
assessment
management
combined
necessitate
multidisciplinary
approach.
emergence
numerous
RCTs
has
shed
light
treatment
This
review
uncovers
epidemiology
intertwined
MASLD,
offers
insights
into
evaluation
hepatic
fibrosis
in
patients
T2DM,
glucose
monitoring
population,
provides
comprehensive
co-management
strategies
for
addressing
both
diseases.
Annals of Internal Medicine,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 13, 2025
Metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
is
the
most
common
chronic
in
United
States.
It
characterized
by
steatosis
and
potentially
reversible.
Risk
factors
include
obesity,
type
2
mellitus,
other
metabolic
disorders.
steatohepatitis
(MASH),
a
more
severe
form
of
MASLD,
puts
patients
at
risk
for
cirrhosis,
decompensation,
cancer.
Diet,
exercise,
weight
loss
are
cornerstones
management.
Although
only
1
medication
has
been
approved
treatment
MASH,
pharmacotherapies
surgeries
that
aid
optimize
can
be
used.
Early
diagnosis
intervention
important
to
prevent
progression
cirrhosis
its
complications,
including
Journal of Hepatology,
Journal Year:
2024,
Volume and Issue:
81(5), P. 837 - 846
Published: June 8, 2024
Survodutide
is
a
glucagon/glucagon-like
peptide-1
receptor
dual
agonist
in
development
for
the
treatment
of
metabolic
dysfunction-associated
steatohepatitis
(MASH).
We
investigated
pharmacokinetic
and
safety
profile
survodutide
people
with
cirrhosis.
Diabetes Care,
Journal Year:
2024,
Volume and Issue:
47(4), P. 544 - 555
Published: March 25, 2024
This
statement
provides
guidance
for
diabetes
care
in
detention
facilities.
It
focuses
on
areas
where
the
processes
delivery
of
to
people
with
facilities
may
differ
from
those
community,
and
key
points
are
made
at
end
each
section.
Areas
emphasis,
which
inform
multiple
aspects
discussed
this
statement,
include
1)
timely
identification
or
diagnosis
treatment
needs
continuity
(at
reception/intake,
during
transfers,
upon
discharge),
2)
nutrition
physical
activity,
3)
access
management
tools
(insulin,
blood
glucose
monitoring,
tracking
data,
current
technologies,
etc.),
4)
whole
person
(self-management
education,
mental
health
support,
monitoring
addressing
long-term
complications,
specialty
care,
etc.).
Annals of Internal Medicine,
Journal Year:
2024,
Volume and Issue:
177(6), P. ITC81 - ITC96
Published: June 1, 2024
Type
2
diabetes
(T2D)
is
a
prevalent
disease
that
increases
risk
for
vascular,
renal,
and
neurologic
complications.
Prevention
treatment
of
T2D
its
complications
are
paramount.
Many
advancements
in
care
have
emerged
over
the
past
5
years,
including
increased
understanding
importance
early
intensive
glycemic
control,
mental
health,
social
determinants
healthy
eating
patterns,
continuous
glucose
monitoring,
benefits
some
drugs
preventing
cardiorenal
disease.
This
review
summarizes
evidence
supporting
prevention
treatment,
focusing
on
aspects
commonly
purview
primary
physicians.
Liver International,
Journal Year:
2025,
Volume and Issue:
45(4)
Published: March 12, 2025
ABSTRACT
Metabolic
dysfunction‐associated
steatotic
liver
disease
(MASLD)
has
become
the
most
common
chronic
globally.
MASLD
is
a
multisystem
where
metabolic
dysfunction
plays
key
role
in
development
of
and
its
relevant
liver‐related
morbidities
extrahepatic
complications,
such
as
cardiovascular
disease,
kidney
certain
types
cancers.
Among
least
examined
MASLD‐related
an
ever‐increasing
number
observational
studies
have
reported
positive
association
between
risk
serious
bacterial
infections
(SBI)
requiring
hospital
admission.
This
remained
significant
those
statistical
analysis
was
adjusted
for
age,
sex,
ethnicity,
obesity,
type
2
diabetes
other
comorbidities.
Notably,
incidence
rates
SBI
were
further
increased
with
more
advanced
MASLD,
especially
patients
cirrhosis,
also
observed
some
acute
viral
infections,
including
SARS‐CoV‐2
infection,
leading
to
severe
COVID‐19.
In
this
narrative
review
article,
we
provide
overview
literature
on
(a)
recent
epidemiological
data
linking
non‐bacterial
admission,
(b)
putative
underlying
mechanisms
through
which
may
increase
susceptibility
both
directly
immune
associated
cirrhosis
portal
hypertension,
(c)
practical
clinical
implications
growing
global
population
MASLD.
